Advocacy groups file brief to support Boehringer’s dispute against FTC
The US Chamber of Commerce and the Association of Corporate Counsel (ACC) have filed an amicus curiae brief in support of Boehringer Ingelheim Pharmaceuticals in its dispute with the Federal Trade Commission (FTC).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
1 June 2017 The Federal Trade Commission’s attempt to obtain Boehringer Ingelheim’s documents relating to a patent dispute settlement would “eviscerate attorney-client privilege”, Boehringer told a US court on Friday, May 26.
1 June 2017 The Federal Trade Commission’s attempt to obtain Boehringer Ingelheim’s documents relating to a patent dispute settlement would “eviscerate attorney-client privilege”, Boehringer told a US court on Friday, May 26.
1 June 2017 The Federal Trade Commission’s attempt to obtain Boehringer Ingelheim’s documents relating to a patent dispute settlement would “eviscerate attorney-client privilege”, Boehringer told a US court on Friday, May 26.